Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
Bruce D. Wines(Burnet Institute), P. Mark Hogarth(Burnet Institute), Halina M. Trist(Burnet Institute), Klasina Chappin(Burnet Institute), Nicholas A. Gherardin(Peter Doherty Institute), Sheila K. Patel(The University of Melbourne), Wai‐Hong Tham(The University of Melbourne), Li‐Jin Chan(The University of Melbourne), Stephen J. Kent(The University of Melbourne), Sandra Esparon(Burnet Institute), Menno C. van Zelm(Erasmus MC), Wen Shi Lee(The University of Melbourne), Liriye Kurtovic(Burnet Institute), Dale I. Godfrey(Peter Doherty Institute), Kanta Subbarao(Peter Doherty Institute), Phillip Pymm(The University of Melbourne), Francesca L. Mordant(The University of Melbourne), James P. Cooney(The University of Melbourne), Amy W. Chung(The University of Melbourne), James G. Beeson(Burnet Institute), Louise M. Burrell(Austin Health), Ester López(The University of Melbourne), Gemma E. Hartley(Monash University), Adam K. Wheatley(The University of Melbourne)
Cited by 15
Related Papers
Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
|The EMBO Journal|2020|499
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
|Nature Medicine|2020|490
CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency
|Journal of Clinical Investigation|2010|387